This fresh investment shall convert to stock in the next substantial circular of preferred equity funding. THE BUSINESS announced two additions to the senior management team also. Simon S. Jones, Ph.D., was appointed Vice President, Biology and Preclinical Development and John H. Van Duzer, Ph.D., was appointed Vice President, Manufacturing and Chemistry. Acetylon is applying its scientific expertise to the development of small molecule HDAC inhibitors that build upon the established therapeutic potential of HDAC inhibition with enhanced focus on selectivity. The ongoing organization believes that its highly selective HDAC inhibitors may accomplish enhanced clinical utility by reducing or eliminating the debilitating and occasionally life-threatening side effects associated with the current first-generation of nonselective HDAC inhibitors.Statistics for the cervical screening programme in England display that around 4,500 deaths per year are prevented. Researchers have calculated that you will see 20 also,000 fewer deaths from bowel cancer over the next 20 years because of the roll-out of the bowel tumor screening programme. In England the number of eligible women attending cervical smear tests improved from simply above 40 per cent in 1989 to 82 percent in 1995.